Experimental
LL-37 (Cathelicidin)
The prediction game
Call it: rising or fading?
Where does LL-37 (Cathelicidin) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: D (early evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 4.7/10
The practical verdict is simple: LL-37 is a fascinating molecule with one promising topical use and a genuine double-edge, which is exactly why it sits in caution rather than higher. If you are drawn to it, the only route with human evidence is topical wound care, and even that rests on one small trial of 34 people. For the injectable systemic use the grey market sells, you would be dosing a confirmed autoimmune trigger and documented cancer growth factor with zero human efficacy data behind it, which is a poor trade no matter how good the mechanism reads. The score reflects that balance honestly: a rich, broad mechanism pulled down by thin human proof and a real intrinsic risk that lands hardest on people with any autoimmune or cancer history. Watch the research closely, but do not mistake an impressive mechanism for a proven therapy. ✅ Best for: Researchers and clinicians who want to understand a uniquely versatile host-defense peptide and its role in immunity, wound healing, and disease. People specifically interested in topical wound care who accept that the evidence is one small trial and that the lowest dose worked best, per Gronberg 2014. People who would rather raise their own cathelicidin the proven way, by correcting vitamin D, per Liu 2006. Anyone with no autoimmune or cancer history who still wants to follow this peptide's science closely before any use. ❌ Avoid if: You have any personal or family history of psoriasis, lupus, or rheumatoid arthritis, since LL-37 is a confirmed autoimmune trigger and autoantigen, per Lande 2014. You have any active, prior, or suspected cancer, since it is a documented growth factor for lung, ovarian, and breast cancer cells, per von Haussen 2008. You want a proven systemic immune or repair peptide, because human efficacy data for injectable LL-37 is zero. You cannot verify source quality, since it is sold unregulated as a research chemical with no purity or sterility guarantee.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 0.1%
- BioHarmony Score
- 4.7/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.